Jan Skvarka, President & CEO, Director at Trillium Therapeutics, holds 0.00 shares in Trillium Therapeutics (Ticker: TRIL), holds 89.55K shares in Zentalis Pharmaceuticals (Ticker: ZNTL), holds ― shares in Monte Rosa Therapeutics (Ticker: GLUE). Most recently, Jan Skvarka ― shares of Trillium Therapeutics on ― for an estimated value of ―.
What is the percentage of profitable transactions made by Jan Skvarka?
The percentage of profitable transactions made by Jan Skvarka is ―.
What is the average return per transaction made by Jan Skvarka?
The average return per transaction made by Jan Skvarka is ―.
What stocks does Jan Skvarka hold?
Jan Skvarka holds: TRIL, ZNTL, GLUE stocks.
What was Jan Skvarka’s latest transaction?
Jan Skvarka latest transaction was an Uninformative Buy of ―.
What was Jan Skvarka's most profitable transaction?
Jan Skvarka’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Jan Skvarka's role in Trillium Therapeutics?
Jan Skvarka's role in Trillium Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.